Recently, Changzhou Qianhong Bio-Pharma targeted anti-cancer Class 1 new drug QHRD110 capsules was approved for clinical trials.
Shanghai Medicilon provided a complete set of preclinical research services including drug efficacy, pharmacokinetics and safety evaluation, as well as registration and declaration services in the research and development of QHRD110 capsules to help the project succeed Clinically approved.
As a new small molecule CDK4/6 inhibitor independently developed by Qianhong with independent intellectual property rights, the proposed indication is advanced malignant solid tumors. QHRD110 capsules specifically inhibit CDK4/6, thereby arresting the cell cycle in the G1/S phase, and finally inhibiting the proliferation of tumor cells.
Medicilon is honored to participate in the pharmacology research, pharmacokinetic research, safety evaluation, and registration application project of Qianhong’s QHRD110.
Our Preclinical Pharmacokinetics Department has a number of professionals with rich theoretical knowledge and experimental experience for experiment design, experiment implementation, bioanalysis and data analysis. Our Pharmacokinetics Lab has passed the GLP certification by NMPA. Following the guiding principles of ICH, NMPA and FDA. The lab offers in vivo and in vitro pharmacokinetic tests according to the needs of our clients and provide them with complete sets of pharmacokinetic evaluation and optimization services. Our acclaimed quality data collection and efficient experiment can meet our clients’ needs from early drug discovery to new drug filing.
Medicilon has a quality management system for drug safety evaluation based on the internationally certified AAALAC quality standard and compliance with international and domestic GLP regulations.
Since 2008, we have continued to meet international standards and completed high-quality GLP safety evaluation services, establishing a long-term brand effect. Medicilon can perform systematic evaluation services covering multiple toxicity endpoints and has internationally recognized pathology studies to support our safety evaluation studies.
Based on years of rich experience in non-clinical evaluation research, Medicilon scientifically and rigorously designed preclinical research trials according to the characteristics and declaration requirements of QHRD110 capsules, and finally completed various trial tasks with quality and quantity, laying the foundation for the successful approval of the project. solid foundation.
Medicilon hope that QHRD110 will obtain clinical approval, bring more hope of survival to more patients with advanced malignant solid tumors.
Medicilon assists Chipscreen Biosciences' CS12192 to be approved by the FDA
Medicilon Assisted Regor Therapeutics Group's New-generation Tumor-targeting Inhibitor RGT-419B Getting Approved for Clinical Use
Medicilon Assistant| Jimincare's lgE Antibody Drug JYB1904 has been Approved for Clinical Trials
Relevant News
marketing@medicilon.com
